The 2014-2016 Ebola virus outbreak in West Africa was the deadliest in history, 
prompting the evaluation of various drug candidates, including antibody-based 
therapeutics for the treatment of Ebola hemorrhagic fever (EHF). Prior to 2014, 
only convalescent blood products from EHF survivors had been administered to 
newly infected individuals as a form of treatment. However, during the recent 
outbreak, monoclonal antibody cocktails such as ZMapp, ZMAb and MB-003 were 
either tested in a human clinical safety and efficacy trial or provided to some 
based on compassionate grounds. This review aims to discuss the evolution of 
antibody-based treatments for EHF, their clinical trial efficacy and the 
development of new antibody-based therapies currently advancing in preclinical 
testing.